Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1377)	1/31/1998 10:08:00 AM
From: Paul Shield	Read Replies (2) \| Respond to of 2205

Marshall, DLJ did review ATIS and ORG. To my eyes their review of ORG was more favorable than of ATIS. I also hear that they are coming out with a strong buy recommendation on ORG shortly. Don't worry I won't buy the stock. I am interested in knowing from the Sturza aficionados why you believe what he writes. To believe someone you need to trust him. When he can write in his special report from today and I quote just the first sentence, "Althought the FDA Advisory Panel on General and Plastic Surgery Devices recommended, in a split 5-to-4 vote a limited approval for Graftskin,...." how can you trust him? That is a blatent lie. The advisory panel was 9-0 for approval of "Apligraf" (he can't even get the name right) but voted 5 to 4 to recommend UNCONDITIONAL approval. The rest of his advisory is full of lies, distortions and misrepresentations or presents strawmen that can be shot down but are irrelevant. Please tell me why you believe and trust him -- i admit it, I don't get it.